High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k “Helper” Proteins
Kamila Gwiazda(Seattle Children's Hospital), Andrew M. Scharenberg(CTI BioPharma (Italy)), David J. Rawlings(Center for Infectious Disease Research), Julia Yang(Bluebird Bio (United States)), Michelle C. Krutein(University of Washington), Unja Martin(Biogen (United States)), Michael C. Jensen(Seattle Children's Hospital), Nicholas A. Popp(University of Washington), Alexandra E. Grier, Iram Khan, Jaya Sahni(Dallas VA Medical Center), Kyle Jacoby
Cited by 35
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Identification of a ligand for the c-kit proto-oncogene
|Cell|1990|954